Faculty Profiles - KUDO Risa

Papers - KUDO Risa

Division display >> ／ All the affair displays 1 - 77 of about 77

HPV関連中咽頭癌・婦人科癌積極的勧奨中止後のHPV16/18型感染率の上昇

黒澤めぐみ, 工藤梨沙, 山口真奈子, 安達聡介, 上田豊, 宮城悦子, 池田さやか, 八木麻未, 吉原弘祐, 関根正幸, 榎本隆之

日本癌治療学会学術集会抄録集 62回 OSY13 - 4 2024.10

【子宮頸がん撲滅へ向けた戦略-ワクチンと検診の新たなトレンドは?】HPVワクチン 9価HPVワクチンの効果

工藤梨沙, 関根正幸, 榎本隆之

臨床婦人科産科 78 ( 6 ) 496 - 502 2024.6

Language：Japanese Publisher：(株)医学書院

＜文献概要＞●9価HPVワクチン(シルガード9)はHPV6/11/16/18/31/33/45/52/58型の感染を予防するワクチンである.日本人子宮頸がんの約9割に関与している7種類のHPVの感染を予防することができる.●諸外国に後れを取ってきたが,本邦でも2023年4月から定期接種として公費で接種できるようになり,15歳の誕生日の前日までに初回接種を行った場合には,2回接種(6ヵ月以上間隔を空ける)で完了とすることができる.●HPVワクチンの積極的接種勧奨が中止された期間に接種機会を逃がした人(1997～2007年度に生まれた女性)に対しても公費で接種する機会(キャッチアップ接種)が与えられている.

日本人若年女性におけるHPVワクチン接種歴の自己申告と自治体接種記録との乖離

黒澤めぐみ, 関根正幸, 山口真奈子, 工藤梨沙, 安達聡介, Hanley Sharon, 上田豊, 八木麻未, 宮城悦子, 池田さやか, 榎本隆之

日本癌治療学会学術集会抄録集 61回 O69 - 1 2023.10

ペグフィルグラスチムによる大動脈炎をきたした1例

菖野悠里子, 西野幸治, 谷地田希, 齋藤宏美, 工藤梨沙, 磯部真倫, 西川伸道, 関根正幸, 榎本隆之

産婦人科の実際 72 ( 6 ) 639 - 644 2023.6

Language：Japanese Publisher：金原出版(株)

＜文献概要＞症例は73歳女性。子宮体癌II期に対してTC療法を実施中にGrade 4の好中球減少を認め,次サイクルにペグフィルグラスチムの予防投与を行ったところ,TC療法day 13(ペグフィルグラスチム投与11日目)に発熱・炎症反応の上昇を認めた。FN(febrile neutropenia)を疑い抗菌薬投与を開始するも改善がみられず,原因精査のために行ったCT/MRIにて上行大動脈～下行大動脈の壁肥厚と周囲の脂肪織濃度を認め,G-CSF製剤による大動脈炎と診断した。ステロイド投与も検討したが,本例においては抗菌薬中止・経過観察のみで大動脈炎は軽快した。G-CSF製剤使用時に,抗菌薬不応性の不明熱と炎症反応の上昇を認めた際には,鑑別診断として大型血管炎に留意する必要がある。

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00535&link_issn=&doc_id=20230627060020&doc_link_id=10.18888%2Fsp.0000002590&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000002590&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

HPVワクチン積極的勧奨再開までの道のりと今後の課題

関根正幸, 黒澤めぐみ, 山口真奈子, 工藤梨沙, 安達聡介, 榎本隆之

日本臨床細胞学会雑誌 62 ( Suppl.1 ) 122 - 122 2023.5

【ヒトパピローマウイルス(HPV)-ワクチン接種の積極的勧奨にあたり知っておくべき知識-】子宮頸がんにおけるHPVワクチンの安全性と有効性,今後の課題

黒澤めぐみ, 関根正幸, 山口真奈子, 工藤梨沙, 榎本隆之

ENTONI ( 281 ) 1 - 11 2023.3

Language：Japanese Publisher：(株)全日本病院出版会

有効性に関しては,世界からHPV感染率や前がん病変の減少に加えて浸潤がんの減少効果が報告されている.本邦においても積極的勧奨中止前のHPVワクチン接種率の高かった世代を対象とした研究で,HPV感染率や前がん病変の減少に関する報告が相次いでいる.一方で,安全性についての検討も国内外で行われており,いずれもHPVワクチンの安全性を否定するものではないことが報告されている.WHOは2020年1月に「接種ストレス関連反応(immunization stress-related responses:ISRR)」という概念を提唱し,これらの状況を受けて2022年4月には積極的勧奨が再開され,キャッチアップ接種も開始された.キャッチアップ接種に関しては,20代以降の効果がまだ不明確であることや,HPVワクチン接種の国家データベースが存在しないことなどの課題が残っている.今後は本邦においても,浸潤がんおよびキャッチアップ接種の有効性を検証する必要がある.(著者抄録)

【HPVワクチン推進を目指して】HPVワクチンキャッチアップ接種の効果と限界

工藤梨沙, 関根正幸, 榎本隆之

日本医師会雑誌 151 ( 12 ) 2066 - 2066 2023.3

骨盤臓器脱に対する腹腔鏡下仙骨子宮靱帯固定術の検討

霜鳥真, 小林暁子, 登内恵理子, 黒澤めぐみ, 明石英彦, 鈴木美保, 工藤梨沙, 磯部真倫, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 117 ( 1 ) 31 - 31 2022.12

HPVワクチンの現在と今後 HPVワクチンの有効性

工藤梨沙, 関根正幸, 黒澤めぐみ, 山口真奈子, 安達聡介, 榎本隆之

日本癌治療学会学術集会抄録集 60回 OWS34 - 2 2022.10

HPVワクチンの現在と今後 HPVワクチンの有効性

工藤梨沙, 関根正幸, 黒澤めぐみ, 山口真奈子, 安達聡介, 榎本隆之

日本癌治療学会学術集会抄録集 60回 OWS34 - 2 2022.10

Problems with catch-up HPV vaccination after resumption of proactive recommendations

Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J B Hanley, Yutaka Ueda, Megumi Kurosawa, Sosuke Adachi, Etsuko Miyagi, Megumi Hara, Takayuki Enomoto

The Lancet Oncology 23 ( 8 ) 972 - 973 2022.8

【HPVワクチン勧奨再開-いま知りたいことのすべて】HPVワクチンの有効性 2価・4価ワクチンを使用した日本・海外における臨床データ

黒澤めぐみ, 山口真奈子, 工藤梨沙, 関根正幸, 榎本隆之

臨床婦人科産科 76 ( 8 ) 754 - 761 2022.8

Language：Japanese Publisher：(株)医学書院

＜文献概要＞●世界からはHPV感染率や前がん病変の減少のみならず,浸潤子宮頸がんに対するHPVワクチンの有効性が報告されている.●日本においても積極的勧奨中止前のHPVワクチン接種率の高かった世代でHPV感染率や前がん病変に対するワクチンの効果を認めている.●日本では積極的勧奨中止による影響で,HPV16/18型感染率が上昇しており,将来的な子宮頸がんリスクの上昇が懸念される.

ペグフィルグラスチムによる大動脈炎を来した一例

菖野悠里子, 西野幸治, 登内恵里子, 霜鳥真, 黒澤めぐみ, 明石絵里菜, 斎藤宏美, 谷地田希, 鈴木美保, 工藤梨沙, 南川高廣, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 西川伸道, 関根正幸, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 64回 294 - 294 2022.7

当院における子宮頸癌術後再発に関する検討

鈴木美保, 西川伸道, 霜鳥真, 明石絵里菜, 工藤梨沙, 南川高廣, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 西野幸治, 関根正幸, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 64回 232 - 232 2022.7

当院における子宮頸癌術後再発に関する検討

鈴木美保, 西川伸道, 霜鳥真, 明石絵里菜, 工藤梨沙, 南川高廣, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 西野幸治, 関根正幸, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 64回 232 - 232 2022.7

Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity. International journal

Risa Kudo, Masayuki Sekine, Manako Yamaguchi, Megumi Hara, Sharon J B Hanley, Megumi Kurosawa, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

Cancer science 113 ( 9 ) 3211 - 3220 2022.6

Language：English Publishing type：Research paper (scientific journal)

Japanese girls aged 12-16 years are offered free human papillomavirus (HPV) vaccination and cervical cancer screening is conducted with cytology and not HPV testing from the age of 20 years. So far, no study has analyzed the effect of HPV vaccination against cervical precancers considering HPV infection status and sexual activity. We aimed to analyze the vaccine effectiveness (VE) against HPV infection and cytological abnormalities, adjusted for sexual activity. This study comprised women aged 20-26 years who underwent cervical screening in Niigata. We obtained HPV vaccination status from municipal records and a questionnaire along with information concerning sexual activity. Of 5194 women registered for this study, final analyses included 3167 women in the vaccinated group (2821 vaccinated women prior to sexual debut) and 1386 women in the unvaccinated group. HPV 16/18 (0.2% vs 3.5%), 31/45/52 (3.4% vs 6.6%), and 31/33/45/52/58 (5.0% vs 9.3%) positive rates were significantly lower in the vaccinated group (P < 0.001). No women vaccinated before sexual debut had HPV 16/18-related cytological abnormalities. VE for HPV 16/18 infection and high-grade cytological abnormalities in women vaccinated prior to sexual debut were 95.8% (95% CI 81.9-99.0%; P < 0.001) and 78.3% (95% CI 11.3-94.7%; P = 0.033), respectively, in multivariate analyses adjusted for age and number of sexual partners. However, analyses of all vaccinated women did not show significant effectiveness against cytological abnormalities. Our results showed the effectiveness of HPV vaccine against high-grade cervical cytological abnormalities and the importance of the vaccination before sexual debut.

DOI： 10.1111/cas.15471

【HPVワクチンのこれまでとこれから-国際的評価を踏まえた課題-】日本の動向と今後の課題 HPVワクチン有効性のエビデンス新潟スタディ

工藤梨沙, 関根正幸, 榎本隆之

産科と婦人科 89 ( 6 ) 623 - 627 2022.6

Language：Japanese Publisher：(株)診断と治療社

AMED榎本班として新潟大学で実施しているNIIGATA STUDYは、子宮頸がん検診時にHPV検査とアンケート調査をあわせて行う横断研究である。自治体記録による正確なHPVワクチン接種歴を用いることと、アンケートによる性的活動性の情報を用いた多変量解析を行っていることが強みである。これまでに20〜22歳を対象にして、HPV16/18型感染に加えて、2価HPVワクチンはHPV31/45/52型感染に対する予防効果を示し、その効果が25〜26歳時点(ワクチン接種から約9年後)も持続していることを確認した。積極的勧奨中止の影響により、ワクチン接種率が激減した学年では、いったんは低下したHPV16/18型感染率が再上昇を認めていることも最近報告した。(著者抄録)

Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data. International journal

Megumi Kurosawa, Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J B Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

Cancer science 113 ( 4 ) 1435 - 1440 2022.4

Language：English Publishing type：Research paper (scientific journal)

In Japan, public funding for HPV vaccination began in 2010 for girls aged 13-16 years (birth cohort years 1994-1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long-term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25-26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993-1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92-109 months). The HPV high-risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross-protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long-term 9-year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.

DOI： 10.1111/cas.15282

HPVワクチン積極的勧奨再開へ向けて

工藤梨沙, 関根正幸, 黒澤めぐみ, 山口真奈子, 安達聡介, 榎本隆之

新潟県医師会報 ( 864 ) 10 - 15 2022.3

重症卵巣過剰刺激症候群の2例

斎藤多佳子, 小林暁子, 黒澤めぐみ, 齋藤宏美, 谷地田希, 工藤梨沙, 島英里, 南川高廣, 石黒竜也, 磯部真倫, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 116 ( 2 ) 70 - 70 2022.3

子宮頸部筋腫に対する腹腔鏡下単純子宮全摘術側方処理のメルクマール

渡部はるか, 小林暁子, 安田麻友, 黒澤めぐみ, 齋藤宏美, 鈴木美保, 工藤梨沙, 田村亮, 島英里, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 西野幸治, 山口雅幸, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 116 ( 2 ) 65 - 65 2022.3

腹腔鏡下仙骨腟固定術術後再発に関する検討

安田麻友, 小林暁子, 黒澤めぐみ, 齋藤宏美, 鈴木美保, 工藤梨沙, 田村亮, 島英里, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 西野幸治, 山口雅幸, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 116 ( 2 ) 62 - 62 2022.3

腟式子宮全摘術後にリスク低減卵管卵巣摘出術を施行した一例

黒澤めぐみ, 西野幸治, 安田麻友, 明石絵里菜, 齋藤宏美, 鈴木美保, 工藤梨沙, 田村亮, 島英里, 須田一暁, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 山口雅幸, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 116 ( 2 ) 58 - 58 2022.3

当院における保険適応下のリスク低減卵管卵巣摘出術(RRSO)の導入と実施状況

黒澤めぐみ, 西野幸治, 武藤恵里, 明石絵里菜, 齋藤宏美, 谷地田希, 鈴木美保, 工藤梨沙, 須田一暁, 石黒竜也, 南川高廣, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 西川伸道, 関根正幸, 榎本隆之, 利川千絵, 諸和樹, 池内健, 入月浩美, 栗山洋子, 藤田沙緒里

新潟産科婦人科学会会誌 116 ( 2 ) 57 - 57 2022.3

Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. International journal

Megumi Kurosawa, Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J B Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

Vaccines 10 ( 2 ) 2022.2

Language：English Publishing type：Research paper (scientific journal)

The preventive effect of HPV vaccines against anogenital and oropharyngeal cancers has been proven in both clinical trials and real-world data. We reviewed the published evidence about the long-term efficacy and effectiveness of the HPV vaccine in available papers of clinical trials and real-world data. As far as we searched, the longest period of preventive effect for the bivalent, 4-valent, and 9-valent vaccine were 11 years in the Costa Rica trial, 14 years in the FUTURE II, and 8 years in the LTFU extension study of V503-002 and the Scandinavian study, respectively. The sustained clinical effect during the observation period was longest for the 4-valent vaccine. In real-world data, the longest observation period of the vaccine effectiveness was 12 years in an Australian study for the 4-valent vaccine. On the other hand, the longest period of long-term persistence of HPV vaccine-induced seropositivity was 14 years in FUTURE II for the 4-valent vaccine. For the bivalent vaccine, additional long-term follow-up studies may not have been planned due to the launch of the 4-valent and 9-valent vaccines. In some studies of the 9-valent vaccine, the results have not yet been published because of the short observation period. The additional results are expected in the future. In a national immunization program, most girls and boys are inoculated with HPV vaccine by the time puberty begins; thus, it is important to monitor the vaccine effect at least until the sexually active period in their 20s and 30s.

DOI： 10.3390/vaccines10020256

【婦人科疾患合併妊娠まるごと図解イチから学ぶ病態生理〜妊娠・分娩管理】トピックス HPVワクチンの最新の話題

工藤梨沙, 関根正幸, 榎本隆之

ペリネイタルケア 41 ( 2 ) 173 - 177 2022.2

【婦人科疾患合併妊娠まるごと図解イチから学ぶ病態生理〜妊娠・分娩管理】トピックス HPVワクチンの最新の話題

工藤梨沙, 関根正幸, 榎本隆之

ペリネイタルケア 41 ( 2 ) 173 - 177 2022.2

多血症を呈しエリスロポエチン産生が疑われた閉経後子宮筋腫の一例

佐藤仁美, 島英里, 谷地田希, 齋藤宏美, 工藤梨沙, 磯部真倫, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

日本産科婦人科学会雑誌 74 ( 臨増 ) S - 519 2022.2

多血症を呈しエリスロポエチン産生が疑われた閉経後子宮筋腫の一例

佐藤仁美, 島英里, 谷地田希, 齋藤宏美, 工藤梨沙, 磯部真倫, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

日本産科婦人科学会雑誌 74 ( 臨増 ) S - 519 2022.2

Cervical Cancer Protection in Japan: Where Are We? International journal

Asami Yagi, Yutaka Ueda, Mamoru Kakuda, Satoshi Nakagawa, Kosuke Hiramatsu, Ai Miyoshi, Eiji Kobayashi, Toshihiro Kimura, Megumi Kurosawa, Manako Yamaguchi, Sosuke Adachi, Risa Kudo, Masayuki Sekine, Yukio Suzuki, Akiko Sukegawa, Sayaka Ikeda, Etsuko Miyagi, Takayuki Enomoto, Tadashi Kimura

Vaccines 9 ( 11 ) 2021.11

Language：English Publishing type：Research paper (scientific journal)

In Japan, government subsidies for human papillomavirus (HPV) vaccination of girls aged 13-16 commenced in 2010. By early 2013, vaccination had become a widely accepted national immunization program. However, in June of 2013, the Ministry of Health, Labor, and Welfare (MHLW), the government's lead agency, suspended its recommendation for vaccination in response to reports of adverse vaccine events. The rate of HPV vaccination quickly dropped from 70% to almost zero, where it has lingered for eight years. In 2020, a new 9-valent HPV vaccine was licensed in Japan. The momentum seemed to be building for the resumption of HPV vaccinations, yet Japanese mothers remain widely hesitant about vaccinating their daughters, despite the well-proven safety and efficacy of the HPV vaccines. The Japanese government and our educational and medical institutions must work harder as a team to inform our parents and their children about the life-saving benefits of the HPV vaccine, and at the same time, we must respond to all their concerns and questions. The vaccine hesitancy of unvaccinated women born in 2000 and thereafter is a natural consequence of the suspension of the government's recommendation. We must also take every possible measure to reduce the significant risk for cervical cancer these women have.

DOI： 10.3390/vaccines9111263

Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data

Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J.B. Hanley, Yutaka Ueda, Sosuke Adachi, Megumi Kurosawa, Etsuko Miyagi, Megumi Hara, Takayuki Enomoto

The Lancet Regional Health - Western Pacific 16 100300 - 100300 2021.11

HPV関連癌(子宮頸癌および中咽頭癌)における診療の現状と予防への展望子宮頸癌予防におけるHPVワクチン有効性の実証

関根正幸, 黒澤めぐみ, 山口真奈子, 工藤梨沙, 安達聡介, 榎本隆之

日本癌治療学会学術集会抄録集 59回 SSY4 - 3 2021.10

HPV関連癌(子宮頸癌および中咽頭癌)における診療の現状と予防への展望子宮頸癌予防におけるHPVワクチン有効性の実証

関根正幸, 黒澤めぐみ, 山口真奈子, 工藤梨沙, 安達聡介, 榎本隆之

日本癌治療学会学術集会抄録集 59回 SSY4 - 3 2021.10

HPVワクチンの積極的勧奨中止の影響によるHPV16/18型感染率の再上昇

工藤梨沙, 関根正幸, 山口真奈子, 黒澤めぐみ, 安達聡介, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 327 - 327 2021.7

卵黄嚢腫瘍に酷似する組織所見を呈した卵巣明細胞癌の一例

島英里, 西野幸治, 黒澤めぐみ, 田村亮, 磯部真倫, 安達聡介, 安田麻友, 齋藤宏美, 工藤梨沙, 鈴木美保, 石黒竜也, 吉原弘祐, 小林暁子, 西川伸道, 関根正幸, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 223 - 223 2021.7

当院における保険適用下のリスク低減卵管卵巣摘出術(RRSO)の導入と実施状況

黒澤めぐみ, 西野幸治, 安田麻友, 齋藤宏美, 鈴木美保, 工藤梨沙, 島英里, 田村亮, 須田一暁, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 西川伸道, 関根正幸, 榎本隆之, 利川千絵, 諸和樹, 永橋昌幸

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 259 - 259 2021.7

子宮体癌における卵巣転移症例の臨床病理学的特徴の検討

谷地田希, 吉原弘祐, 安田麻友, 黒澤めぐみ, 齋藤宏美, 鈴木美保, 工藤梨沙, 島英里, 田村亮, 石黒竜也, 安達聡介, 磯部真倫, 小林暁子, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 312 - 312 2021.7

当院における保険適用下のリスク低減卵管卵巣摘出術(RRSO)の導入と実施状況

黒澤めぐみ, 西野幸治, 安田麻友, 齋藤宏美, 鈴木美保, 工藤梨沙, 島英里, 田村亮, 須田一暁, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 小林暁子, 西川伸道, 関根正幸, 榎本隆之, 利川千絵, 諸和樹, 永橋昌幸

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 259 - 259 2021.7

HPVワクチンの積極的勧奨中止の影響によるHPV16/18型感染率の再上昇

工藤梨沙, 関根正幸, 山口真奈子, 黒澤めぐみ, 安達聡介, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 327 - 327 2021.7

子宮体癌における卵巣転移症例の臨床病理学的特徴の検討

谷地田希, 吉原弘祐, 安田麻友, 黒澤めぐみ, 齋藤宏美, 鈴木美保, 工藤梨沙, 島英里, 田村亮, 石黒竜也, 安達聡介, 磯部真倫, 小林暁子, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 312 - 312 2021.7

HPVワクチンの現状有効性と安全性

工藤梨沙, 関根正幸, 山口真奈子, 黒澤めぐみ, 安達聡介, 榎本隆之

新潟県臨床検査技師会誌 61 ( 2 ) 50 - 57 2021.4

HPV16型感染が確認されながらp16免疫染色が陰性であったVIN3の若年症例

櫛谷直寿, 小林暁子, 工藤梨沙, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 西野幸治, 山口雅幸, 西川伸道, 関根正幸, 榎本隆之

日本産科婦人科学会雑誌 73 ( 臨増 ) S - 295 2021.3

クロミフェンクエン酸塩療法後のheterotopic pregnancyに対する腹腔鏡下手術経験

石黒竜也, 櫛谷直寿, 齋藤宏美, 工藤梨沙, 茅原誠, 西野幸治, 小林暁子, 山口雅幸, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 115 ( 2 ) 137 - 137 2021.3

完全直腸脱を伴うstage IV骨盤臓器脱に対して腹腔鏡下直腸固定術と同時に腹腔鏡下仙骨腟固定術を行った2症例

春谷千智, 小林暁子, 明石英彦, 鈴木美保, 工藤梨沙, 茅原誠, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 115 ( 2 ) 81 - 85 2021.3

Language：Japanese Publisher：新潟産科婦人科学会

症例1は80歳で、約2年前から子宮下垂感を自覚し、約1年前から排便時に直腸脱を認めるようになった。今回、Stage IVの子宮脱および完全直腸脱の診断で一期的根治手術を行う方針となり、腹腔鏡下にWells直腸後方固定術+子宮腟上部切断+両側付属器切除+シングルメッシュによる仙骨腟固定術を施行し、術後経過良好であった。症例2は78歳で、約2年前から子宮脱を自覚し、間欠的自己還納で対応していた。半年前に排尿困難感が出現し、手術目的で当科を紹介受診した。初回受診時は子宮脱のみであったが、2回目の診察で直腸脱の併発を認めた。今回、Stage IVの子宮脱および完全直腸脱の診断で症例1と同様の手術を行い、術後経過良好であった。

【ワクチンの安全性と社会学-HPVワクチンの接種はなぜ広まらないのか?-】HPVワクチンについて HPVワクチンの有効性最近の動向

関根正幸, 工藤梨沙, 山口真奈子, 安達聡介, 黒澤めぐみ, 榎本隆之

産婦人科の実際 70 ( 3 ) 285 - 291 2021.3

Language：Japanese Publisher：金原出版(株)

＜文献概要＞HPVワクチンの積極的勧奨が中止されて8年が経過しようとしている。HPVワクチン接種者が検診年齢である20歳に到達したことで,HPV感染率の低下だけでなく,細胞診異常と組織診異常の低下も報告されてきている。NIIGATA STUDYではHPV16/18型感染に対する高い有効性に加え,HPV31/45/52型に対する交叉防御効果が示され,厚生労働科学研究費補助金上田班とAMED榎本班のJ Studyでは,それぞれCIN3以上の減少効果,CIN2以上の減少効果が示された。海外では,スウェーデンから世界で初めて浸潤子宮頸癌の減少効果が報告され,わが国でも浸潤癌に対するデータの検証が待たれている。

Risk factors for HPV infection and high-grade cervical disease in sexually active Japanese women. International journal

Manako Yamaguchi, Masayuki Sekine, Sharon J B Hanley, Risa Kudo, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Takayuki Enomoto

Scientific reports 11 ( 1 ) 2898 - 2898 2021.2

Language：English Publishing type：Research paper (scientific journal)

In Japan, recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears. Although vaccine opponents claim modifying sexual behavior can prevent cervical cancer, no comprehensive data exist on sexual behavior and the risk of high-grade cervical disease in a Japanese population. This study investigates sexual behavior and the risk of HPV infection and cervical disease in 3968 women aged 20-41 yrs undergoing cervical screening between April 2014 and March 2016. Mean age at first intercourse was 18.4 yrs ± 2.8 and 32% of women reported ≥ 6 lifetime sexual partners. In regression analyses, number of partners was a significant risk factor for HPV infection. However, for high-grade disease (CIN2+), when HPV genotype was adjusted for, number of partners was not statistically significant. The greatest risk factor was an HPV16/18 infection (adjusted odds ratio 113.7, 95% CI: 40.8-316.9). In conclusion, we found that having an HPV16/18 infection and not sexual behavior was the most significant risk factor for high grade cervical disease in young Japanese women. These infections can be prevented by a highly effective vaccine and we recommend that the Japanese government resume proactive recommendations for the HPV vaccine immediately.

DOI： 10.1038/s41598-021-82354-6

Internet Survey of Awareness and Behavior Related to HPV Vaccination in Japan. International journal

Risa Kudo, Masayuki Sekine, Manako Yamaguchi, Megumi Hara, Sharon J B Hanley, Yutaka Ueda, Asami Yagi, Sosuke Adachi, Megumi Kurosawa, Etsuko Miyagi, Takayuki Enomoto

Vaccines 9 ( 2 ) 2021.1

Language：English Publishing type：Research paper (scientific journal)

Recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears in Japan. We aimed to clarify the differences between vaccinated and unvaccinated females in their awareness, knowledge, and behaviors toward cervical cancer, HPV vaccination and sex. Questionnaires were administered online to women aged 16 to 20. We conducted investigations for the following: awareness, knowledge, and actions for cervical cancer, HPV vaccination, and sexual activity, as well as items related to participants' social background. The survey in 828 girls revealed three points. The first is that more than half of the surveyed Japanese girls had poor knowledge about cervical cancer screening, HPV, or HPV vaccines. The second is that those in the unvaccinated group had a particularly poor knowledge of the subject and tended to have higher sexual activity. The final is that only 0.5% of the girls experienced changes in awareness about sexual activity after vaccination. In conclusion, this is the first large-scale survey analyzing the association between HPV vaccination and sexual activity in Japanese girls. Not only do unvaccinated girls not benefit from vaccines, but they also tend to engage in high-risk sexual behavior, and thus it is even more important to provide information on the effectiveness of vaccines and the usefulness of cancer screening.

DOI： 10.3390/vaccines9020087

日本人女性における性的活動性とHPV感染、子宮頸部組織診異常との関係

山口真奈子, 関根正幸, 工藤梨沙, 安達聡介, 榎本隆之

新潟産科婦人科学会会誌 115 ( 1 ) 37 - 37 2021.1

日本人若年女性におけるHPV9価ワクチン導入効果の予測

山口真奈子, 関根正幸, 工藤梨沙, 安達聡介, 榎本隆之

日本婦人科腫瘍学会雑誌 39 ( 1 ) 277 - 277 2021.1

腹腔鏡下手術におけるセプラフィルム体腔内搬入および貼付法の工夫 Endoロールの使用経験

鈴木美保, 小林暁子, 黒澤めぐみ, 明石英彦, 明石絵里菜, 工藤梨沙, 田村亮, 石黒竜也, 安達聡介, 吉原弘祐, 磯部真倫, 西野幸治, 山口雅幸, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 115 ( 1 ) 1 - 6 2021.1

Language：Japanese Publisher：新潟産科婦人科学会

セプラフィルムは優れた癒着防止効果が報告されているが、腹腔鏡下手術での体腔内搬入や貼付操作に難渋することが多い。今回、セプラフィルムの操作にEndoロールを用いた方法を試行し、その有効性について従来法(リデューサーを用いる方法)と比較検討した。腹腔鏡下単純子宮全摘出術3例にEndoロールを使用した結果、3例とも充填が比較的簡便に途中で破損することなく可能であった。最も優れていた点は、5mmポートから挿入可能なため、カメラで確認しながら安全に体腔内搬入でき、周囲臓器にセプラフィルムが付着する前に、広がったままの状態で受け取ることにより貼付が容易な点であった。

当科における腹腔鏡下仙骨腟固定術の治療成績

明石英彦, 小林暁子, 春谷千智, 明石絵里菜, 鈴木美保, 工藤梨沙, 田村亮, 安達聡介, 磯部真倫, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 115 ( 1 ) 25 - 30 2021.1

Language：Japanese Publisher：新潟産科婦人科学会

骨盤臓器脱に対して2018年6月〜2020年2月に腹腔鏡下仙骨腟固定術を行った31例のうち、直腸脱の同時手術を行った2例を除く29例を対象とし、「手術時間」「術中出血量」「術中・術後合併症」「再発の有無」「術前後の排尿機能」などについて検討した。手術時間は128〜256分(中央値199分)、出血量は5〜10mL(中央値5mL)であった。術中合併症は認めなかった。術後合併症として腹腔内感染を1例に認めたが保存的治療で改善した。再発は1例に認め、再発部位はメッシュ固定部位以外の後壁であり、追加手術は要しなかった。排尿機能はOABSSとIPSSで評価し、術前のOABSSは軽症(5点以下)5例、中等症(6〜11点)6例、術後のOABSSは軽症1例、中等症1例、重症(12点以上)1例であった。術前のIPSSは軽症(0〜7点)50%、中等症(8〜19点)35%、重症(20〜35点)15%、術後のIPSSは軽症81%、中等症15%、重症4%であった。

A survey of 20-year-old Japanese women: how is their intention to undergo cervical cancer screening associated with their childhood HPV vaccination status?

Reisa Kakubari, Tomomi Egawa-Takata, Yutaka Ueda, Yusuke Tanaka, Asami Yagi, Akiko Morimoto, Yoshito Terai, Masahide Ohmichi, Tomoyuki Ichimura, Toshiyuki Sumi, Hiromi Murata, Hidetaka Okada, Hidekatsu Nakai, Noriomi Matsumura, Kiyoshi Yoshino, Tadashi Kimura, Junko Saito, Risa Kudo, Masayuki Sekine, Takayuki Enomoto, Yorihiko Horikoshi, Tetsu Takagi, Kentaro Shimura

Human Vaccines and Immunotherapeutics 17 ( 2 ) 434 - 442 2021

Publishing type：Research paper (scientific journal)

© 2020 Taylor & Francis Group, LLC. Introduction: In Japan, two groups of women, HPV vaccinated and unvaccinated, are approaching age 20, when they should begin cervical cancer screening. To improve Japan’s current poor cervical cancer screening rate, we need to know how these women are thinking about screening. Methods: We conducted an internet survey of 20-y-old women, exploring their understanding of HPV and cervical cancer screening. We then gave them leaflets with basic information about HPV and cervical cancer, stressing the importance of early detection by screening. We analyzed the leaflet’s effects on their attitudes based on their vaccination status. Results: Our study of 618 women found a significantly higher intention for engagement for cervical cancer screening in women HPV-vaccinated as teenagers (29% versus 17%). They were also more aware that: (1) HPV is transmitted by sexual intercourse (49.1% versus 39.2%); (2) the HPV vaccine prevents cervical cancer (49.0% to 34.0%); and (3) the appropriate cervical cancer screening interval is every 2 y (63.3% versus 56.2%). Women in both groups responded well to the leaflet, with significant improvements in intention to receive screening. However, 65%-67% were not swayed. Discussion: HPV-vaccinated women were more knowledgeable about cervical cancer and had a greater intention to receive screening. Our educational leaflet was moderately effective in both groups for increasing intentions to screen, but the majority in both groups were still resistant to screening. Conclusion: Japan needs to develop more effective educational programs and tools to vigorously impart the importance of cervical cancer screening.

DOI： 10.1080/21645515.2020.1788326

Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination. International journal

Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J B Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

Vaccines 8 ( 3 ) 2020.7

Language：English Publishing type：Research paper (scientific journal)

Organized human papillomavirus vaccination (OHPV) in Japan was introduced in 2010 for girls aged 12-16 years who were born in 1994 or later. The rate of OHPV coverage was 70-80%. However, after suspension of the government vaccination recommendation, the coverage dramatically decreased. We aim to investigate the change in prevalence of HPV infection after the initiation of HPV vaccination. We recruited females aged 20-21 years attending public cervical cancer screening from 2014 to 2017 fiscal years (April 2014 to March 2018). Residual Pap test specimens were collected for HPV testing. We compared the prevalence of HPV type-specific infection between women registered in 2014 (born in 1993-1994, including the pre-OHPV generation) and registered in 2015-2017 (born in 1994-1997, the OHPV generation). We collected 2379 specimens. The vaccination coverage figures were 30.7%, 86.6%, 88.4% and 93.7% (p < 0.01) from 2014 to 2017, respectively. The prevalence of HPV16/18 infection significantly decreased from 1.3% in 2014 to 0% in 2017 (p = 0.02). The three most prevalent types were HPV52, 16 and 56 in 2014, and HPV52, 58 and 56 in 2015-2017, respectively. HPV16 and 33 infection rates decreased. On the other hand, the HPV58 infection rate was obviously increased after OHPV from 0.3% to 2.1%. Our study demonstrates that the prevalence of HPV16/18 infection dramatically decreased and the profile of type-specific HPV infection was changed after OHPV.

DOI： 10.3390/vaccines8030425

Japan's Ongoing Crisis on HPV Vaccination. International journal

Masayuki Sekine, Risa Kudo, Manako Yamaguchi, Sharon J B Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

Vaccines 8 ( 3 ) 2020.7

Language：English Publishing type：Research paper (scientific journal)

: The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also lower in the vaccinated group, and the vaccine effectiveness was 67.7%. Furthermore, prevalence of HPV16, 31 and 52 infection rates in the vaccinated group were obviously lower than that in the unvaccinated group, and no one had HPV18 or 45 infection in the vaccinated group. The addition of a cross-protective effect toward HPV types 31/45/52 to HPV types 16/18, which is the direct target of the bivalent HPV vaccine, may possibly prevent around 82% of invasive cervical cancer cases in Japan. With regard to the preventive effect of histological abnormalities, we also reported significant reduction in incidence of cervical intraepithelial neoplasia (CIN)3 or worse. Thus, the efficacy of the vaccine has been demonstrated for precancerous disease, and the diverse symptoms after HPV vaccination are likely functional somatic. For the future of Japanese girls, there is a need to resume the proactive recommendation of HPV vaccination and for immediate action to be taken by the Japanese government.

DOI： 10.3390/vaccines8030362

【子宮頸がん予防-日本はどうする?-】HPVワクチン接種プログラムのインパクト-日本の現状と課題-

工藤梨沙, 関根正幸

産婦人科の実際 69 ( 3 ) 257 - 262 2020.3

Language：Japanese Publisher：金原出版(株)

＜文献概要＞わが国においてヒトパピローマウイルス(HPV)ワクチンは2009年に認可され,2010年に自治体ごとの公費接種助成が開始し,接種対象年齢の女性は無料でワクチン接種が可能となった。2013年には国が定める定期接種ワクチンの1つとなったが,現在は積極的勧奨が中止されており,新規のワクチン接種者がほぼいない状況が継続している。その一方で,積極的勧奨中止前にワクチンを接種した公費接種対象世代が子宮頸がん検診の対象年齢となっており,諸外国と同様にわが国からも若年女性におけるHPVワクチンによるHPV感染率と前がん病変発症率の減少効果に関するデータが続々と報告されてきた。本稿では,わが国におけるHPVワクチン接種の現状と子宮頸がん予防に対する今後の課題について解説する。

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00535&link_issn=&doc_id=20200403100012&doc_link_id=10.18888%2Fsp.0000001212&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000001212&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

HPVワクチン公費接種の導入による若年世代のHPV感染プロファイルの変化

山口真奈子, 関根正幸, 工藤梨沙, 安達聡介, 榎本隆之

新潟産科婦人科学会会誌 113 ( 2 ) 85 - 85 2019.2

【子宮頸がんとHPVワクチンを考える】HPVワクチンの有効性最近の動向

関根正幸, 工藤梨沙, 山口真奈子, 安達聡介, 榎本隆之

外来小児科 22 ( 1 ) 55 - 60 2019.2

Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection. International journal

Risa Kudo, Manako Yamaguchi, Masayuki Sekine, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Megumi Hara, Sharon J B Hanley, Takayuki Enomoto

The Journal of infectious diseases 219 ( 3 ) 382 - 390 2019.1

Language：English Publishing type：Research paper (scientific journal)

Background: Proactive recommendations for human papillomavirus (HPV) vaccines in Japan have been suspended for 5 years because of safety concerns. While no scientific evidence exists to substantiate these concerns, one reason given for not reinstating recommendations is the lack of reliable vaccine effectiveness (VE) data in a Japanese population. This study reports the VE of the bivalent HPV vaccine in Japanese women aged 20-22 years. Methods: During cervical screening between 2014 and 2016, women had Papanicolaou smears and HPV tests performed and provided data about their sexual history. Estimates of VE for vaccine-targeted HPV type 16 (HPV16) and 18 and cross-protection against other types were calculated. Results: Overall, 2197 women were tested, and 1814 were included in the analysis. Of these, 1355 (74.6%) were vaccinated, and 1295 (95.5%) completed the 3-dose schedule. In women sexually naive at vaccination, the pooled VEs against HPV16 and 18 and for HPV31, 45, and 52 were 95.5% (P < .01) and 71.9% (P < .01), respectively. When adjusted for number of sex partners and birth year, pooled VEs were 93.9% (P = .01) and 67.7% (P = .01) for HPV16 and 18 and HPV31, 45, and 52, respectively. Conclusions: The bivalent HPV vaccine is highly effective against HPV16 and 18. Furthermore, significant cross-protection against HPV31, 45, and 52 was demonstrated and sustained up to 6 years after vaccination. These findings should reassure politicians about the VE of bivalent HPV vaccine in a Japanese population.

DOI： 10.1093/infdis/jiy516

Differential misclassification between self-reported status and official HPV vaccination records in Japan: Implications for evaluating vaccine safety and effectiveness. International journal

Manako Yamaguchi, Masayuki Sekine, Risa Kudo, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Megumi Hara, Sharon J B Hanley, Takayuki Enomoto

Papillomavirus research (Amsterdam, Netherlands) 6 6 - 10 2018.12

Language：English Publishing type：Research paper (scientific journal)

Japan has no national vaccine registry and approximately 1700 municipalities manage the immunization records independently. In June 2013, proactive recommendations for the human papillomavirus (HPV) vaccine were suspended after unconfirmed reports of adverse events following immunization in the media, despite no vaccine safety signal having been raised. Furthermore, studies assessing HPV vaccine safety and effectiveness published post suspension are predominantly based on self-reported information. Our aim was to examine the accuracy of self-reported vaccination status compared with official municipal records. Participants were women aged 20-22 yrs, who were attending for cervical screening in Niigata city. Among the 1230 eligible registrants, vaccine uptake, defined as any dose, was 75.0% and 77.2% according to a self-reported questionnaire and municipal records, respectively. The accuracy rate of self-reported information was as follows: positive predictive value (PPV) was 87.7%; negative predictive value (NPV) was 54.5%; sensitivity was 85.2%; and specificity was 59.8%. The validity of self-reported information was only moderate (Kappa statistic = 0.44, 95% confidence interval 0.37-0.50). This combined with the low NPV may lead to reduced estimation of effectiveness and safety. A more reliable method, such as a national HPV vaccine registry, needs to be established for assessing HPV immunization status in Japan.

DOI： 10.1016/j.pvr.2018.05.002

HPVワクチン接種による子宮頸がん検診細胞診異常例におけるハイリスクHPV感染率の変化

工藤梨沙, 関根正幸, 山口真奈子, 安達聡介, 八木麻美, 上田豊, 原めぐみ, Hanley Sharon, 宮城悦子, 榎本隆之

日本癌治療学会学術集会抄録集 56回 PS - 6 2018.10

帝王切開既往症例における膀胱挙上、癒着に対する腹腔鏡下子宮全摘術時の膀胱剥離の定型化

小林暁子, 磯部真倫, 上田遥香, 小木幹奈, 工藤梨沙, 茅原誠, 石黒竜也, 吉原弘祐, 安達聡介, 西野幸治, 西川伸道, 関根正幸, 榎本隆之

新潟産科婦人科学会会誌 113 ( 1 ) 21 - 25 2018.9

Language：Japanese Publisher：新潟産科婦人科学会

腹腔鏡下子宮全摘術(TLH)を施行した既往帝王切開31例を対象とし、定型化した帝王切開術後の膀胱剥離法を開始前の3例(42〜51歳)と開始後28例(41〜62歳)であった。手術適応では、開始後で子宮体癌の症例数が11例と多かった。開腹への移行、膀胱損傷など、手技に関係する術中・術後の合併症は認めなかった。入院期間、手術時間に顕著な差は認めなかったが、出血量は開始後で少ない傾向にあった。

日本人若年女性のsexual activityとHPV感染、子宮頸部細胞診異常との相関

山口真奈子, 工藤梨沙, 安達聡介, 関根正幸, 八木麻未, 田中佑典, 上田豊, 宮城悦子, 榎本隆之

日本癌治療学会学術集会抄録集 55回 P165 - 1 2017.10

日本人若年女性におけるHPVワクチン公費接種者のHPV感染予防効果

工藤梨沙, 山口真奈子, 安達聡介, 関根正幸, 八木麻未, 田中佑典, 上田豊, 宮城悦子, 榎本隆之

日本癌治療学会学術集会抄録集 55回 PS - 6 2017.10

Realistic fear of cervical cancer risk in Japan depending on birth year. International journal

Asami Yagi, Yutaka Ueda, Tomomi Egawa-Takata, Yusuke Tanaka, Ruriko Nakae, Akiko Morimoto, Yoshito Terai, Masahide Ohmichi, Tomoyuki Ichimura, Toshiyuki Sumi, Hiromi Murata, Hidetaka Okada, Hidekatsu Nakai, Masaki Mandai, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura, Junko Saito, Yumiko Hori, Eiichi Morii, Tomio Nakayama, Yukio Suzuki, Yoko Motoki, Akiko Sukegawa, Mikiko Asai-Sato, Etsuko Miyagi, Manako Yamaguchi, Risa Kudo, Sosuke Adachi, Masayuki Sekine, Takayuki Enomoto, Yorihiko Horikoshi, Tetsu Takagi, Kentaro Shimura

Human vaccines & immunotherapeutics 13 ( 7 ) 1700 - 1704 2017.7

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: In Japan, the possible adverse events upon HPV vaccination was widely reported in the media. MHLW announced the suspension of aggressively encouraging HPV vaccination in 2013, and inoculation rate has sharply declined. The aim of the present study was estimation of future cervical cancer risk. METHODS: The latest data on vaccination rate at each age in Sakai City were first investigated. The rate of experiencing sexual intercourse at the age of 12, 13, 14, 15, 16, 17 and throughout lifetime is assumed to be 0%, 1%, 2%, 5%, 15%, 25%, and 85% respectively. The cervical cancer risk was regarded to be proportional to the relative risk of HPV infection over the lifetime. The risk in those born in 1993 whom HPV vaccination was not available yet for was defined to be 1.0000. RESULTS: The cumulative vaccination rates were 65.8% in those born in 1994, 72.7% in 1995, 72.8% in 1996, 75.7% in 1997, 75.0% in 1998, 66.8% in 1999, 4.1% in 2000, 1.5% in 2001, 0.1% in 2002, and 0.1% in 2003. The relative cervical cancer risk in those born in 1994-1999 was reduced to 0.56-0.70, however, the rate in those born in 2000-2003 was 0.98-1.0, almost the same risk as before introduction of the vaccine. DISCUSSION: The cumulative initial vaccination rates were different by the year of birth. It is confirmed that the risk of future cervical cancer differs in accordance with the year of birth. For these females, cervical cancer screening should be recommended more strongly.

DOI： 10.1080/21645515.2017.1292190

新潟市におけるHPV感染と細胞診異常の現状、および性活動性との相関

山口真奈子, 工藤梨沙, 安達聡介, 関根正幸, 榎本隆之, 田中佑典, 森本晶子, 高田友美, 上田豊

日本婦人科腫瘍学会雑誌 35 ( 3 ) 584 - 584 2017.6

ヒトパピローマウイルス(HPV)検査におけるハイリスクスクリーニング法とジェノタイピング法による結果不一致例の検討

工藤梨沙, 関根正幸, 山口真奈子, 安達聡介, 榎本隆之, 上田豊, 高田友美, 森本晶子, 田中佑典, 八木麻未

日本産科婦人科学会雑誌 69 ( 2 ) 674 - 674 2017.2

Project conducted in Hirakata to improve cervical cancer screening rates in 20-year-old Japanese: Influencing parents to recommend that their daughters undergo cervical cancer screening. International journal

Asami Yagi, Yutaka Ueda, Tomomi Egawa-Takata, Yusuke Tanaka, Yoshito Terai, Masahide Ohmichi, Tomoyuki Ichimura, Toshiyuki Sumi, Hiromi Murata, Hidetaka Okada, Hidekatsu Nakai, Masaki Mandai, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura, Junko Saito, Yumiko Hori, Eiichi Morii, Tomio Nakayama, Yukio Suzuki, Yoko Motoki, Akiko Sukegawa, Mikiko Asai-Sato, Etsuko Miyagi, Manako Yamaguchi, Risa Kudo, Sosuke Adachi, Masayuki Sekine, Takayuki Enomoto, Yorihiko Horikoshi, Tetsu Takagi, Kentaro Shimura

The journal of obstetrics and gynaecology research 42 ( 12 ) 1802 - 1807 2016.12

Language：English Publishing type：Research paper (scientific journal)

AIM: In Japan, the rate of routine cervical cancer screening is quite low, and the incidence of cervical cancer has recently been increasing. Our objective was to investigate ways to effectively influence parental willingness to recommend that their 20-year-old daughters undergo cervical cancer screening. METHODS: We targeted parents whose 20-year-old daughters were living with them. In fiscal year 2013, as usual, the daughter received a reminder postcard several months after they had received a free coupon for cervical cancer screening. In fiscal year 2014, the targeted parents received a cervical cancer information leaflet, as well as a cartoon about cervical cancer to show to their daughters, with a request that they recommend to their daughter that she undergo cervical cancer screening. The subsequent screening rates for fiscal years 2013 and 2014 were compared. RESULTS: The cervical cancer screening rate of 20-year-old women whose parents received the information packet in fiscal year 2014 was significantly higher than for the women who, in fiscal year 2013, received only a simple reminder postcard (P < 0.001). As a result, the total screening rate for 20-year-old women for the whole of the 2014 fiscal year was significantly increased over 2013 (P < 0.001). CONCLUSION: For the first time, we have shown that the parents of 20-year-old daughters can be motivated to recommend that their daughters receive their first cervical cancer screening. This was achieved by sending a cervical cancer information leaflet and a cartoon about cervical cancer for these parents to show to their daughters. This method was significantly effective for improving cervical cancer screening rates.

DOI： 10.1111/jog.13122

Mothers' attitudes in Japan regarding cervical cancer screening correlates with intention to recommend cervical cancer screening for daughters.

Tomomi Egawa-Takata, Yutaka Ueda, Yusuke Tanaka, Akiko Morimoto, Satoshi Kubota, Asami Yagi, Yoshito Terai, Masahide Ohmichi, Tomoyuki Ichimura, Toshiyuki Sumi, Hiromi Murata, Hidetaka Okada, Hidekatsu Nakai, Masaki Mandai, Kiyoshi Yoshino, Tadashi Kimura, Junko Saito, Risa Kudo, Masayuki Sekine, Takayuki Enomoto, Yorihiko Horikoshi, Tetsu Takagi, Kentaro Shimura

International journal of clinical oncology 21 ( 5 ) 962 - 968 2016.10

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Cervical cancer and its precancerous lesions caused by human papilloma virus (HPV) are steadily increasing in women in Japan. In comparison with women in other resource-rich countries, young women in Japan have a dismally low screening rate for cervical cancer. Our preliminary research has shown that 20-year-old women in Japan usually ask their mothers for advice regarding their initial cervical cancer screening. The objective of our current research is to determine the social factors among mothers in Japan that are causing them to give advice to their daughters regarding the HPV vaccine and cervical cancer screening. METHODS: The survey's targets were mothers who had 20-year-old daughters. We recruited respondents from the roster of a commercial internet survey panel. We analyzed for correlations between a mother's knowledge concerning cervical cancer, her recent cancer screening history, and the advice she gave to her daughter regarding cervical cancer screening. RESULTS: We obtained 618 valid answers to the survey. Compared with mothers who did not get screening, mothers who had cervical cancer screening had significantly more knowledge about cervical cancer and its screening (p < 0.05). The daughters of mothers with recent screening had received HPV vaccination more often than those of mothers without recent screening (p = 0.018). Mothers with recent screening histories tended more often to encourage their daughters to have cervical cancer screening (p < 0.05). When mothers were properly educated concerning cervical cancer and its screening, they were significantly more likely than before to recommend that their daughters have it (p < 0.0001). CONCLUSIONS: In young Japanese women, given the important role their mothers have in their lives, it is probable that we could improve their cervical cancer screening rate significantly by giving their mothers better medical information, and a chance to experience cervical cancer screening for themselves.

子宮子宮頸がん検診と予防新潟市におけるHPV感染と性活動性調査

工藤梨沙, 関根まさゆき, 山口真奈子, 安達聡介, 田中佑介, 森本晶子, 高田友美, 上田豊, 榎本隆之

日本癌治療学会学術集会抄録集 54回 WS60 - 2 2016.10

HPVワクチン接種と性活動性に関するインターネット調査

工藤梨沙, 関根正幸, 安達聡介, 田中研介, 森本晶子, 高田友美, 上田豊, 榎本隆之

新潟産科婦人科学会会誌 111 ( 1 ) 42 - 42 2016.7

20-21歳女性におけるHPVワクチン接種とHPV感染率、および性活動性との相関

関根正幸, 山口真奈子, 工藤梨沙, 安達聡介, 田中佑典, 森本晶子, 高田友美, 八木麻未, 上田豊, 榎本隆之

日本婦人科腫瘍学会雑誌 34 ( 3 ) 411 - 411 2016.6

20-21歳女性におけるHPVワクチン接種とHPV感染率および性活動性との相関

関根正幸, 山口真奈子, 工藤梨沙, 安達聡介, 榎本隆之, 上田豊, 高田友美, 森本晶子, 田中佑典, 八木麻未

日本産科婦人科学会雑誌 68 ( 2 ) 825 - 825 2016.2

子宮子宮頸がん検診と予防子宮頸がん予防行動と性活動性に関するインターネット調査

工藤梨沙, 関根正幸, 安達聡介, 田中佑典, 森本晶子, 高田友美, 上田豊, 榎本隆之

日本癌治療学会誌 50 ( 3 ) 1196 - 1196 2015.9

20歳の女性の母親に対するインターネット調査若年者の子宮がん検診受診率向上を目指して

八木麻未, 上田豊, 高田友美, 森本晶子, 田中佑典, 吉野潔, 工藤梨沙, 関根正幸, 榎本隆之, 木村正

日本がん検診・診断学会誌 23 ( 1 ) 53 - 53 2015.8

若年女性におけるHPV感染と性活動性および細胞診異常との相関

工藤梨沙, 関根正幸, 安達聡介, 田中佑典, 森本晶子, 高田友美, 上田豊, 榎本隆之

日本婦人科腫瘍学会雑誌 33 ( 3 ) 594 - 594 2015.6

若年女性におけるHPV感染と性活動性および細胞診異常との相関

工藤梨沙, 関根正幸, 井上清香, 榎本隆之, 上田豊, 高田友美, 森本晶子

日本産科婦人科学会雑誌 67 ( 2 ) 653 - 653 2015.2

Laparoscopic Surgery for Patients with Early Stage Endometrial Cancer Reviewed

Adachi Sosuke, Yahata Tetsuro, Kudo Risa, Yamagishi Yoko, Yamawaki Kaoru, Suda Kazuaki, Tamura Ryo, Chihara Makoto, Ishiguro Tatsuya, Minamikawa Takahiro, Banzai Chiaki, Nishino Koji, Nishikawa Nobumichi, Kashima Katsunori, Enomoto Takayuki

JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY 29 ( 1 ) 313 - 317 2013.11

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：JAPAN SOCIETY OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY AND MINIMALLY INVASIVE THERAPY

Laparoscopy has been widely proposed as an alternative to a laparotomy for the treatment of early stage endometrial cancer. The purpose of this study was to assess the efficacy, safety, and prognosis of laparoscopic surgery. We retrospectively analyzed the results of laparoscopic surgery for patients with early stage endometrial cancer at the Department of Obstetrics and Gynecology, Niigata University Medical & Dental Hospital between 2003 and 2011. A total of 44 patients underwent laparoscopic surgery by three different surgeons. Blood loss and number of lymph nodes removed were not statistically significant between surgeons. Although a significant difference in surgery time (P = 0.0017) was initially observed between surgeons, this difference became insignificant as the surgeons gained experience. With increasing surgeons' experience, laparoscopic surgery is useful for the treatment of early stage endometrial cancer.

DOI： 10.5180/jsgoe.29.313

Other Link： http://search.jamas.or.jp/link/ui/2014188363

　 PREV - NEXT 　

1